JOURNAL ARTICLE

A potential role for onabotulinumtoxinA in the management of Hallucinogen persisting perception disorder.

  • Published In: Australasian Psychiatry, 2023, v. 31, n. 2. P. 230 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Ryan, Ella; Kulkarni, Jayashri 3 of 3

Abstract

Since then, TJ has had anxiety and depressive symptoms, severe chronic headaches, and reoccurrence of perceptual disturbances experienced during hallucinogen intoxication. Dear Sir, Hallucinogen persisting perception disorder (HPPD) is a rare syndrome characterised by the continued experience of perceptual symptoms despite the cessation of hallucinogen use.[1] There are no established guidelines for pharmacological treatment of HPPD, with treatment largely informed by case reports. TJ also reported recurrence of symptoms of anxiety and depression, which he attributed to return of the headaches and perceptual disturbances. [Extracted from the article]

Additional Information

  • Source:Australasian Psychiatry. 2023/04, Vol. 31, Issue 2, p230
  • Document Type:Article
  • Subject Area:Science
  • Publication Date:2023
  • ISSN:1039-8562
  • DOI:10.1177/10398562231154107
  • Accession Number:162993409
  • Copyright Statement:Copyright of Australasian Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.